Adaptimmune CEO Adrian Rawcliffe at EUBIO22 (Rachel Kiki for Endpoints News)
March 6, 2023 07:19 AM EST
Deals
Cell/Gene Tx

Months af­ter re­org, Adap­ti­m­mune merges with fel­low cell ther­a­py de­vel­op­er

Amber Tong

Adap­ti­m­mune is merg­ing with TCR² Ther­a­peu­tics in a bid to cre­ate a T cell ther­a­py de­vel­op­er aimed at sol­id tu­mors.

The

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times